Tazanolast, an anti-allergic and anti-asthmatic agent with selective mast-cell stabilising effects, was developed jointly by Wakamoto and Torii Pharmaceuticals.

Diamminedichlorodihydroxyplatinum IV is the platinum-based antineoplasticis agent. Oxaliplatin is cis, cis, trans- isomer of Diamminedichlorodihydroxyplatinum IV. Oxaliplatin show high stability and therefore can be utilized orally for outpatient care. Although oxoplatin is capable of binding directly to DNA after prolonged incubation, platinum(IV) agents are considered to be largely inert prodrugs that are converted to highly cytotoxic platinum(II) compounds by reducing substances, enzymes, or microenvironmental conditions. Reaction of oxoplatin with 0.1 M hydrogen chloride mimicking gastric acid yields cis-diammine-tetrachlorido-platinum(IV) (DATCP[IV]), which exhibits two-fold increased activity. The oxoplatin metabolite DATCP(IV) constitutes a potent cytotoxic derivative that may be produced by gastric acid or acidic areas prevailing in larger solid tumors, depending on the respective pharmaceutical formulation of oxoplatin.

Manganese gluconate is a manganese salt of gluconic acid. Manganese gluconate is sometimes used as a food additive for its texture and light pink coloring. As a food additive, manganese gluconate increases satiety, and the texture of processed foods related to mouth feel. However, in recent years, manganese gluconate has been used less and less as a food additive due to its high toxicity. Many food manufacturers have abandoned using manganese gluconate in favor of other chemical compounds that provide similar effects with a lower toxicity. According to the Food and Drug Administration, manganese gluconate is generally recognized as safe, or GRAS. However, high amounts of manganese gluconate intake, upwards of 15 mg per day, may cause potentially serious health risks. Manganese gluconate toxicity may cause a chemical imbalance in the brain, increasing your risk of developing anxiety, depression, nervousness, psychosis, and mania. Manganese gluconate is used for prevention of deficiency and osteoporosis (off-label).

Teneligliptin is a DPP IV inhibitor which was developed by Mitsubishi Tanabe Pharma and now is used for the treatment of type 2 diabetes mellitus in Asia under the name Tenelia.

Mebhydrolin (INN) or mebhydroline is a histamine H1-receptor antagonist. It is not available in the United States, but it is available in various other countries under the brand names Bexidal and Diazolin. It is used for symptomatic relief of allergic symptoms caused by histamine release, including nasal allergies and allergic dermatosis.

Fenquizone is the diuretic drug. The distribution of fenquizone labelled with 14C in mice was studied by means of an autoradiographic technique. High concentration of radioactivity was found in the intestine, liver, kidney, blood, myocardium and skeletal muscles in decreasing order at various times after oral administration. The labelled compound did not cross the blood-brain barrier. Fenquizone is a saluretic with a quinazolone structure which acts by blocking reabsorption of sodium in the proximal tubule and the ascending branch of the loop of Henle, as well as in the proximal section of the convoluted distal tubule. At low doses fenquizone has an hypotensive action without showing the characteristics secondary effects of diuretics so that it can be employed for long-term treatments without any risk. Fenquizone showed also a significant decrease of symptoms (headache, dizziness) due to hypertension. No undesirable side effects were observed.

Sulforidazine (Imagotan (Sandoz); Inofal (Sandoz)) is a typical piperidine-type phenothiazine antipsychotic agent. It is dopamine receptor blocker. Being the second active metabolite of thioridazine (converted from mesoridazine), Sulforidazine is significantly more potent than the parent drug.

Dembrexine is a mucolytic agent which reduces the viscosity of respiratory mucus. It improves movement of mucus in small airways. Dembrexine increases secretion of the serous cells in the glands of the nasal, tracheal and bronchial cells and in type II alveolar cells. It also possesses an anti-tussive effect. Dembrexine is used in the treatment of respiratory disease in horses. All respiratory infections with increased secretions. Acute, sub-acute bronchitis. Chronic respiratory disease. Infection of the upper airways.

Spasmolytic drug pramiverine was used in the active treatment of labor. In addition, it participated in clinical trials for patients with colitis syndrome. It was revealed, that pramiverine had improved the conditions of patients.

Neridronic acid (6-amino-1-idroxyesilidene-1,1-bisphosphonate) is a nitrogen-containing bisphosphonate licensed in Italy for the treatment of osteogenesis imperfecta and Paget’s disease of bone. The pharmacodynamic profile is similar to that of other nitrogen-containing bisphosphonates and is characterized by its high affinity for bone tissue particularly at sites undergoing a process of remodeling. In growing children affected by osteogenesis imperfect, neridronic acid rapidly increases bone mineral density as measured by dual X-ray absorptiometry and this is associated with a significant decrease in fracture cumulative number. Similar results have been obtained also in newborns (<12-month-old) and in adult patients. In Paget’s disease of bone, 200 mg intravenous neridronic acid is associated with a 65% rate of full remission and a biochemical response (decrease of > 75% of bone turnover markers) in 95% of the patients. Neridronic acid treatment has been reported to be effective also in other skeletal diseases such as osteoporosis, algodystrophy, hypercalcemia of malignancy and bone metastasis. Neridronic acid has been developed only for parenteral use, and it is the only one used as the intramuscular injection. This avoids all the limitations of oral bisphosphonates and may be offered for a home treatment with simple nursing assistants